NEW YORK, January 12, 2015 /PRNewswire/ --
Moments ago, Analysts Review released new research updates concerning several important developing situations including Shire (NASDAQ: SHPG), Agenus (NASDAQ: AGEN), Foundation Medicine (NASDAQ: FMI), Silicon Image (NASDAQ: SIMG), and XL Group (NYSE: XL). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
SHPG Research Report: ( http://get.analystsreview.com/pdf/?c=Shire&d=12-Jan-2015&s=SHPG ),
AGEN Research Report: ( http://get.analystsreview.com/pdf/?c=Agenus&d=12-Jan-2015&s=AGEN ),
FMI Research Report: ( http://get.analystsreview.com/pdf/?c=Foundation%20Medicine&d=12-Jan-2015&s=FMI ),
SIMG Research Report: ( http://get.analystsreview.com/pdf/?c=Silicon%20Image&d=12-Jan-2015&s=SIMG ),
XL Research Report: ( http://get.analystsreview.com/pdf/?c=XL%20Group&d=12-Jan-2015&s=XL ).
Analyst Update: Acquisitions and Strategic Collaboration
Reviewed by: Rohit Tuli, CFA®
The U.S. stocks declined on Friday after two consecutive days of advance as concerns over the growth of the world's largest economy revived after disappointing job data for the month of December. According to a Reuters report, U.S. nonfarm payrolls rose in December, beating the market expectations, but wages unexpectedly fell. All the three major U.S. benchmark indices ended the session in red, with S&P 500 index closing at 2,044.81, down 0.84%. The Dow Jones Industrial Average finished 0.95% lower at 17,737.37, and the Nasdaq Composite was down 0.68% at 4,704.07. Investors also turned cautious ahead of the Q4 2014 corporate earnings season. Meanwhile, the European shares closed lower on Friday amid uncertainty ahead of the release of the U.S. nonfarm payroll data and after latest data showed that German exports and industrial output declined in November. Asian markets were mostly higher on Friday, tracking two-day rally in the U.S. and European markets.
Shire Plc (Shire) announced agreement to acquire all the outstanding shares of rare disease-focused biopharmaceutical company NPS Pharmaceuticals, Inc. (NPS Pharma) for a total consideration of approximately $5.2 billion. The acquisition seeks to strengthen Shire's focus on rare diseases while leveraging industry-leading gastrointestinal commercial capabilities and global footprint. Know more about the Shire's latest acquisition, which comes just ahead of FDA decision on NPS Pharma's NAPTARA drug, in our exclusive report.
Delaware-based Incyte Corporation (Incyte) has teamed up with Agenus Inc. (Agenus) to develop novel immuno-oncology antibodies, using Agenus' antibody discovery platform. Incyte will pay Agenus $60 million in upfront payment and up to $350 million in milestones. Following the agreement, shares of Agenus jumped nearly 29% on Friday to hit a new 52-week high. Know more about the collaboration in our exclusive research report.
Foundation Medicine, Inc. (Foundation Medicine) announced that Switzerland-based Roche has agreed to acquire a majority stake in the Company for around $1 billion, as part of a broad, strategic collaboration in the field of molecular information in oncology. Roche will acquire up to 56.3% of Foundation Medicine through a tender and acquisition of newly issued shares. For additional details on this strategic R&D collaboration, please visit our research report.
Shares of the Silicon Image, Inc. (Silicon Image) surged nearly 7% on Friday after Reuters reported that the California-based semiconductor maker is exploring strategic alternatives, including selling itself. The move comes within a month after Silicon Image issued a cautious outlook for its 2015 Mobile revenues. Read more about the story in our detailed research report.
XL Group Plc (XL Group) announced that it has agreed to acquire London-based Catlin Group Limited (Catlin) in a cash and stock transaction valued at approx. $4.1 billion. The combined business is expected to have a leading presence in the global specialty insurance and reinsurance markets. Know more about the transaction and the subsequent reaction of the rating agencies in our exclusive research report.
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review